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Abstract—Chronic urticaria is a challenging problem since the exact cause and mechanism involved
in the disease development have still remained unknown. This disease is associated with mast cells
activation and immunoinﬂammatory processes. Interestingly, dysfunctions of the neuroendocrine–
immune system due to stress and other factors seem to appear as a very interesting theory for
urticaria pathogenesis. Dehydroepiandrosterone and its sulfate derivative (DHEA-S) appear to have
regulatory effects in immune homeostasis and are regulated by the nervous system, and it is sug-
gested that they may be an integral element of neuroimmunomodulation. Our studies showed
substantially decreased serum concentration of DHEA-S in patients with chronic urticaria. However,
current knowledge prevents answering whether lower circulating DHEA-S concentration is a pri-
mary phenomenon or just an accompanying one which appears as a response of different systems to
the course of the illness and may not be of any importance for the pathogenesis of urticaria what-
soever. This review is a summary of clinical research on the role of DHEA in chronic urticaria.
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INTRODUCTION
Chronic urticaria is a condition characterized by
pruritus and wheals, and appears as a challenging
problem for the researchers since the exact cause,
mechanism, and mediators involved in the disease
development have still remained unknown.
This disease is associated with the increased activa-
tion of mast cells and a variety of inﬂammatory and
immunological reactions [1–4]. It is known that there exist
some relationships between hormones and the immune–
inﬂammatory processes. On one hand, hormones regulate
the immune and inﬂammatory response, on the other hand,
the inﬂammatory mediators inﬂuence the hormonal bal-
ance [5]. Interestingly, dysfunctions of the neuroendo-
crine–immune system due to stress and other factors seem
to appear as a very interesting theory for urticaria patho-
genesis [6]. It is known that urticaria may be associated
with some diseases and/or inﬂuenced by some conditions
characterized by sex hormonal changes, including men-
strual cycle, pregnancy, menopause, and hormonal contra-
ceptives or hormone replacement therapy. However, the
role of endogenous and exogenous sex hormones, as well
as estrogenmimetics in the disease pathogenesis are poorly
understood [7]. Dehydroepiandrosterone (DHEA) and its
sulfate derivative (DHEA-S; together abbreviated DHEA-
(S)) are weak androgens produced in the adrenals and serve
as the primary precursor in the biosynthesis of both
androgens and estrogens. In the skin, DHEA-(S) is
converted to androstenediol which consequently is con-
verted to androstenetriol, such metabolic process being
unique to the skin. Because DHEA-(S) and their derivates
appear to have regulatory effects in immune homeostasis
and are regulated by the nervous system, it is suggested
that they may be an integral element of neuroimmunomo-
dulation [8]. Direct neuroprotective effects of DHEA-(S)
have been demonstrated [9]. However, the speciﬁc
mechanisms of their action are unknown. Reduced levels
of DHEA-S have also been noted in individuals with
mental disorders, including depression [10–12] and anxi-
ety [13]. Such deﬁciencies have been associated with
immune-mediated diseases, including organ-speciﬁc and
systemic autoimmune disease as, well as allergic diseases.
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In some of these disorders, clinical improvement has been
observed following oral DHEA administration [14–18].
DHEA-S is involved in the body response to stress
and may play a signiﬁcant role in modulating vulner-
ability of the organism to the negative impact of stress
[19]. The DHEA-S level and DHEA-S–cortisol ratio
may play a role in modulating the consequences of stress
throughout a variety of processes [19].
SERUM CONCENTRATION
OF DEHYDROEPIANDROSTERONE SULFATE
IN PATIENTS WITH CHRONIC URTICARIA
WITH POSITIVE AND NEGATIVE RESPONSE
TO AUTOLOGOUS SERUM SKIN TEST (ASST)
Our studies showed substantially decreased serum
concentration of DHEA-S in patients with chronic
urticaria, regardless their gender and response to ASST
[20–26]. Elderly postmenopausal women, 50–65 years
of age, showed DHEA-S serum concentration similar to
the healthy controls, suggesting the existence of two
different hormonal patterns of DHEA-S circulating
concentration in female patients suffering from chronic
urticaria, depending on age of the disease onset [26].
Some relations between the clinical status (active
disease and upon remission) and DHEA-S concentration
were observed. DHEA-S concentration was signiﬁcantly
lower in symptomatic chronic urticaria patients as
compared to chronic urticaria upon spontaneous remis-
sion, and to the healthy subjects [25]. The data suggest
that lower serum DHEA-S concentration is a transient
phenomenon accompanying chronic urticaria to disappear
during spontaneous remission of the disease [25]. The fact
that the reduction in DHEA-S is observed irrespective of
ASST results implies that this phenomenon does not
depend on the autoimmune/not autoimmune pathogenesis
of the disease. This seems to strengthen the hypothesis
that the observed reduction (which is inversely correlated
with the disease activity) is most probably a nonspeciﬁc
consequence of an inﬂammatory process that occurs in
the skin [27] rather than the cause of the disease itself.
WHY DOES DHEA-S CONCENTRATION
DECREASE IN CHRONIC URTICARIA
PATIENTS?
There are several hypothetical explanations of the
phenomenon of lower circulating concentration of
DHEA-S in chronic urticaria patients. It has been
suggested that during chronic inﬂammatory response
[28] and severe stress conditions [29], a hormonal shift
may occur in the adrenal steroid production into the
direction of cortisol relative to DHEA-(S), which is
probably necessary to achieve adequate cortisol level
at the expense of adrenal androgens [28]. It is
interesting to speculate that similar changes in ste-
roidogenesis might occur in urticaria, inadequate
cortisol level could then partly account for enhanced
urticaria symptoms at night when physiological secre-
tion of cortisol declines. We failed to detect any
changes in the cortisol rhythm between the two
chronic urticaria groups (showing negative and pos-
itive ASST) and the healthy subjects [22]. However, it
is necessary to examine the function of the adreno-
cortical steroidogenic cascade and the hypothalamic–
pituitary–adrenal axis, as well as steroid metabolism in
such patients to clarify comprehensively the behavior
and signiﬁcance of adrenal steroids in urticarial
inﬂammation. Because it has been suggested that
prolactin may regulate DHEA-S secretion [30] and
vice versa [31], we assessed serum concentrations of
prolactin and DHEA-S in urticaria patients. We found
no association between serum DHEA-S and prolactin
concentration in urticaria patients, which might indi-
cate that lower DHEA-S serum concentration could
not be accounted for by changes in prolactin secretion
[22].
Another question is whether there exists any
association between interleukin-6 (IL-6) and DHEA-S
in the peripheral circulation of chronic urticaria patients,
as a functional link between IL-6 and DHEA has been
reported [32, 33]. IL-6 is a proinﬂammatory cytokine
and a marker of systemic inﬂammation [34]. It has been
reported that IL-6 and IL-6R are expressed by adrenal
cells, and IL-6 leads to long-term stimulation of
adrenocortical steroidogenesis, including DHEA-S, sug-
gesting its role in integration of adrenal response to
stimuli from the immune and endocrine systems; it also
seems to be a long-term regulator of the stress response
[32, 33, 35]. In chronic urticaria patients, IL-6 plasma
concentration was slightly elevated and kept within the
normal range. However, no association between DHEA-
S and IL-6 concentrations in the peripheral circulation of
chronic urticaria patients was proven, suggesting that the
phenomena may not be related to each other [23].
The next question to be asked is whether there is
any relationship between DHEA-S serum concentration
and the level of stress in patients with chronic urticaria.
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Bad or negative stress called distress may have a
role in the onset or exacerbation of several disorders and
symptoms in numerous tissues and organs, including the
skin [36–42]. Urticaria symptoms, such as pruritus and
uncomfortable lesions, can appear as a considerable
source of physical and psychological distress [43, 44]. In
addition, Baiardini et al. reported a severe impairment of
quality of life in CU patients [45]. Urticaria patients
showed lower serum concentration of DHEA-S and a
lower level of the sense of coherence, as well as higher
level of anxiety as a state and as a trait, and higher level
of depression. DHEA-S concentration correlated neg-
atively with the level of anxiety as a trait and the level of
depression, and positively with the sense of coherence
level. The results conﬁrm the clinical observations
indicating that chronic urticaria patients do suffer from
psychological distress. Moreover, the correlations may
support the hypothesis that DHEA-S decline observed in
chronic urticaria patients can be a secondary phenom-
enon, resulting from the psychological distress [24].
DHEA-S’s role in urticaria may also be observed
from a different standpoint, where the declining ten-
dency would be considered as a defense response to the
enhanced mast cell activity in the disease. Interestingly,
it has been reported that neurosteroids, which are
synthesized de novo in the central and peripheral
nervous systems, including DHEA-S, may induce mast
cell degranulation through a Gq/11 protein-coupled
membrane receptor [46].
SOME POSSIBLE MECHANISMS BY WHICH
DHEA-S MAY BE INVOLVED
IN THE URTICARIAL PROCESSES
It is noteworthy that DHEA was successfully used
to prevent attacks in hereditary angioedema, where the
effect resulted probably from inhibition of the classical
complement pathway activation [47].
It is interesting to speculate that DHEA(-S) deﬁ-
ciency might facilitate or induce complement activation
involved in pathogenesis of the disease. Moreover, since
these hormones may regulate cell- and humoral-mediated
immunological response, cell proliferation and viability,
as well as cytokine production [48–50], the decline in
circulating DHEA-S concentration might contribute to
initiation and/or maintenance of the immune–inﬂammatory
cascade in the disease, partly by disregulating the
immune response and through the increased inﬂamma-
tory activity.
UNANSWERED QUESTIONS AND NEED
FOR FUTURE RESEARCH
Our current knowledge prevents answering whether
lower circulating concentration of DHEA-S in urticaria is a
primary phenomenon or just an accompanying one which
appears as a response of different systems to the course of
the illness and may not be of any importance for the
pathogenesis of urticaria whatsoever. We suggested that
distress and/or the inﬂammatory state resulted in the relative
DHEA-S deﬁciency. The lack of hormonal alterations
persistence upon clinical inactivity of the disease suggests
that the mechanisms responsible for such change perform
only throughout the active period of the disease [25].
As dehydroepiandrosterone may show the immuno-
modulatory properties and impose some positive effects
upon mood and the quality of life it would be particularly
interesting to examine whether DHEA supplementation
may help to relieve the symptoms of urticaria. It is
noteworthy that danazol, capable of increasing serum
concentration of DHEA-S [51], was successfully used in
the treatment of some cases of chronic urticaria [52].
Explicit understanding of the changes in hormonal
environment may provide the basis to develop new
therapeutic strategies, including those of DHEA.
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